Bio Medica Laboratories (NSE:BMLL) EBIT: ₹ Mil (TTM As of Mar. 2025)


NSE:BMLL Bio Medica Laboratories Ltd NSE:BMLL
14 GF Score
Price ₹144.10
! 2 Warning Signs
View Full Analysis

What is Bio Medica Laboratories EBIT?

Bio Medica Laboratories NSE:BMLL +0.49% 14 EBIT is ₹ Mil as of Mar. 2025. GuruFocus rates NSE:BMLL with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Bio Medica Laboratories's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2025 was ₹144.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bio Medica Laboratories's annualized ROC % for the quarter that ended in Mar. 2025 was 41.99%. Bio Medica Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 63.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Bio Medica Laboratories  (NSE:BMLL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bio Medica Laboratories's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=143.673 * ( 1 - 25.47% )/( (170.581 + 339.391)/ 2 )
=107.0794869/254.986
=41.99 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=195.308 - 24.624 - ( 0.103 - max(0, 65.559 - 105.517+0.103))
=170.581

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=391.179 - 51.72 - ( 0.068 - max(0, 169.943 - 310.912+0.068))
=339.391

Note: The Operating Income data used here is one times the annual (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Bio Medica Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=144.702/( ( (87.271 + max(67.096, 0)) + (74.605 + max(223.396, 0)) )/ 2 )
=144.702/( ( 154.367 + 298.001 )/ 2 )
=144.702/226.184
=63.98 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23.359 + 73.669 + 8.386) - (24.624 + 0 + 13.694)
=67.096

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(41.002 + 181.379 + 88.463) - (51.72 + 0 + 35.728)
=223.396

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bio Medica Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2025 )
=/2192.364
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio Medica Laboratories EBIT Related Terms

Bio Medica Laboratories EBIT Historical Data

* Premium members only.

The historical data trend for Bio Medica Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio Medica Laboratories EBIT Chart

Bio Medica Laboratories Annual Data
Trend Mar23 Mar24 Mar25
EBIT
11.80 45.89 144.70

Bio Medica Laboratories Semi-Annual Data
Mar23 Mar24 Mar25
EBIT 11.80 45.89 144.70

NSE:BMLL vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio Medica Laboratories EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bio Medica Laboratories's EV-to-EBIT falls into.


NSE:BMLL
14GF Score
Bio Medica Laboratories Ltd NSE:BMLL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio Medica Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹ Mil mean?
Bio Medica Laboratories (NSE:BMLL) has a EBIT of ₹ Mil as of Mar. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bio Medica Laboratories.
Is Bio Medica Laboratories' EBIT too high?
Bio Medica Laboratories' current EBIT is ₹ Mil. Overall, Bio Medica Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' EBIT compare to ISRG and BDX?
Bio Medica Laboratories' EBIT of ₹ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bio Medica Laboratories. Bio Medica Laboratories's current EBIT is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current EBIT of ₹ Mil. The current EBIT is ₹ Mil. Bio Medica Laboratories' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current EBIT is ₹ Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio Medica Laboratories Business Description

Address Sanwer Road, Plot No. 11B-11C, Sector-E, Industrial Area, Industrial Estate - Indore, Indore, MP, IND, 452015
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
14GF Score

Get the complete analysis for NSE:BMLL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹144.10
Price